UA94952C2 - 18-метил-19-норандрост-4-ен-17,17-спіроефір (18-метил-19-нор-20-спірокс-4-ен-3-он) і фармацевтичний препарат, який його містить - Google Patents

18-метил-19-норандрост-4-ен-17,17-спіроефір (18-метил-19-нор-20-спірокс-4-ен-3-он) і фармацевтичний препарат, який його містить

Info

Publication number
UA94952C2
UA94952C2 UAA200900433A UAA200900433A UA94952C2 UA 94952 C2 UA94952 C2 UA 94952C2 UA A200900433 A UAA200900433 A UA A200900433A UA A200900433 A UAA200900433 A UA A200900433A UA 94952 C2 UA94952 C2 UA 94952C2
Authority
UA
Ukraine
Prior art keywords
methyl
spiroether
spirox
androst
same
Prior art date
Application number
UAA200900433A
Other languages
English (en)
Russian (ru)
Inventor
Рольф Больманн
Йоахім Кунке
Ян Хюбнер
Норберт Галлус
Фредерік Менгес
Штеффен Борден
Ханс-Петер Мун
Катя Прелле
Original Assignee
Байєр Шерінг Фарма Акцієнгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA94952(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байєр Шерінг Фарма Акцієнгезельшафт filed Critical Байєр Шерінг Фарма Акцієнгезельшафт
Publication of UA94952C2 publication Critical patent/UA94952C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

У даному винаході описані нові 18-метил-19-норандрост-4-ен 17,17-спіроефіри загальної формули І EMBED ISISServer , Формула І у якій Z являє собою атом кисню, два атоми водню, групу =NOR або =NNHSO2R, де R представляє собою атом водню або прямоланцюгову або розгалужену алкільну групу, яка містить від 1 до 4 або від 3 до 4 атомів вуглецю, R4 являє собою атом водню, атом галогену або трифторметильну групу, R6 та/або R7 можуть мати α- або β-конфігурацію, і R6 і R7 незалежно один від одного являють собою атом водню або прямоланцюгову або розгалужену алкільну групу, яка містить від 1 до 4 або від 3 до 4 атомів вуглецю, або прямоланцюгову або розгалужену алкенільну групу, яка містить від 2 до 4 або від 3 до 4 атомів вуглецю, або насичену циклоалкільну групу, яка містить від 3 до 5 атомів вуглецю, або разом являють собою метиленову групу або подвійний зв'язок. Нові сполуки мають дію, яка сприяє настанню або збереженню вагітності, і антимінералокортикоїдну дію.
UAA200900433A 2006-06-29 2007-06-29 18-метил-19-норандрост-4-ен-17,17-спіроефір (18-метил-19-нор-20-спірокс-4-ен-3-он) і фармацевтичний препарат, який його містить UA94952C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006030416A DE102006030416A1 (de) 2006-06-29 2006-06-29 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
PCT/EP2007/005893 WO2008000521A1 (de) 2006-06-29 2007-06-29 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate

Publications (1)

Publication Number Publication Date
UA94952C2 true UA94952C2 (uk) 2011-06-25

Family

ID=38626491

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200900433A UA94952C2 (uk) 2006-06-29 2007-06-29 18-метил-19-норандрост-4-ен-17,17-спіроефір (18-метил-19-нор-20-спірокс-4-ен-3-он) і фармацевтичний препарат, який його містить

Country Status (41)

Country Link
US (1) US7846917B2 (uk)
EP (1) EP2038294B1 (uk)
JP (1) JP5326085B2 (uk)
KR (1) KR101440640B1 (uk)
CN (1) CN101511857B (uk)
AR (1) AR061736A1 (uk)
AT (1) ATE490967T1 (uk)
AU (1) AU2007263944B2 (uk)
BR (1) BRPI0713934A2 (uk)
CA (1) CA2656443C (uk)
CL (1) CL2007001919A1 (uk)
CO (1) CO6150134A2 (uk)
CR (1) CR10548A (uk)
CY (1) CY1111658T1 (uk)
DE (2) DE102006030416A1 (uk)
DK (1) DK2038294T3 (uk)
DO (1) DOP2008000089A (uk)
EC (1) ECSP089014A (uk)
ES (1) ES2357698T3 (uk)
GT (1) GT200800307A (uk)
HK (1) HK1133659A1 (uk)
HN (1) HN2008001934A (uk)
HR (1) HRP20110161T1 (uk)
IL (1) IL195935A0 (uk)
MA (1) MA30596B1 (uk)
MX (1) MX2009000082A (uk)
MY (1) MY155015A (uk)
NO (1) NO20090459L (uk)
NZ (1) NZ573951A (uk)
PE (1) PE20080995A1 (uk)
PL (1) PL2038294T3 (uk)
PT (1) PT2038294E (uk)
RS (1) RS51722B (uk)
RU (1) RU2440365C2 (uk)
SI (1) SI2038294T1 (uk)
TN (1) TNSN08518A1 (uk)
TW (1) TWI413645B (uk)
UA (1) UA94952C2 (uk)
UY (1) UY30451A1 (uk)
WO (1) WO2008000521A1 (uk)
ZA (1) ZA200900673B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
EP2841073A1 (de) 2012-04-23 2015-03-04 Bayer Pharma Aktiengesellschaft ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN BEI DER THERAPIE DER MENORRHAGIA, SOWIE 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE ENTHALTENDE INTRAUTERINE SYSTEME FÜR DIE THERAPIE UTERINEN BLUTUNGSSTÖRUNGEN
WO2015055789A1 (en) 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
TN2016000134A1 (en) * 2013-10-18 2017-10-06 Bayer Oy Intrauterine delivery system.
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) * 2019-01-17 2021-01-26 浙江仙琚制药股份有限公司 替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798213A (en) 1971-01-25 1974-03-19 Merck & Co Inc 7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de) 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1223174A3 (en) 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US8445469B2 (en) 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
PL2038294T3 (pl) 2011-05-31
DOP2008000089A (es) 2009-02-15
PE20080995A1 (es) 2008-10-03
BRPI0713934A2 (pt) 2012-12-04
US7846917B2 (en) 2010-12-07
KR101440640B1 (ko) 2014-09-22
HK1133659A1 (uk) 2010-04-01
UY30451A1 (es) 2008-01-31
CY1111658T1 (el) 2015-10-07
RU2440365C2 (ru) 2012-01-20
MY155015A (en) 2015-08-28
DK2038294T3 (da) 2011-03-28
HN2008001934A (es) 2012-01-17
PT2038294E (pt) 2011-03-14
ES2357698T3 (es) 2011-04-28
EP2038294A1 (de) 2009-03-25
JP2009541405A (ja) 2009-11-26
GT200800307A (es) 2009-11-03
HRP20110161T1 (hr) 2011-04-30
CA2656443A1 (en) 2008-01-03
JP5326085B2 (ja) 2013-10-30
RS51722B (en) 2011-10-31
AU2007263944A1 (en) 2008-01-03
NO20090459L (no) 2009-03-10
NZ573951A (en) 2011-06-30
IL195935A0 (en) 2009-09-01
KR20090021294A (ko) 2009-03-02
CN101511857B (zh) 2012-10-31
RU2009102772A (ru) 2010-08-10
ATE490967T1 (de) 2010-12-15
CN101511857A (zh) 2009-08-19
CR10548A (es) 2009-01-27
ZA200900673B (en) 2010-04-28
MA30596B1 (fr) 2009-07-01
TWI413645B (zh) 2013-11-01
DE502007005902D1 (de) 2011-01-20
TW200811193A (en) 2008-03-01
CL2007001919A1 (es) 2008-05-16
AR061736A1 (es) 2008-09-17
CO6150134A2 (es) 2010-04-20
SI2038294T1 (sl) 2011-04-29
WO2008000521A1 (de) 2008-01-03
TNSN08518A1 (en) 2010-04-14
MX2009000082A (es) 2009-01-23
ECSP089014A (es) 2009-01-30
DE102006030416A1 (de) 2008-01-03
US20080153787A1 (en) 2008-06-26
CA2656443C (en) 2014-10-07
AU2007263944B2 (en) 2013-07-18
EP2038294B1 (de) 2010-12-08

Similar Documents

Publication Publication Date Title
UA94952C2 (uk) 18-метил-19-норандрост-4-ен-17,17-спіроефір (18-метил-19-нор-20-спірокс-4-ен-3-он) і фармацевтичний препарат, який його містить
TW200745114A (en) Novel compounds
TNSN08024A1 (en) 7-substituted aza-indazoles, compositions containing same, production method and use thereof
LUC00065I1 (uk)
TW200800999A (en) Novel compounds
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
EA200800415A1 (ru) Удаление пероксида из носителя для доставки лекарственного средства
NO20081160L (no) Benzimidazoltiofen forbindelser
MX2009013354A (es) Compuestos de triarilo y composiciones que los contienen.
ECSP088854A (es) Moduladores bencimidazolicos de vr1
TW200621313A (en) Pharmaceutical compositions
UA86591C2 (uk) Піролодигідроізохіноліни як інгібітори pde10, фармацевтична композиція на їх основі
ATE485261T1 (de) Salicylsäurederivate
TW200640857A (en) Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
TW200613317A (en) Steroid prodrugs with androgenic action
GEP20094604B (en) NEW ASSOCIATION OF A SINUS NODE if CURRENT INHIBITOR AND AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
CY1108916T1 (el) Υποκαθιστουμενες πυρρολες, οι ενωσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση τους
TW200732345A (en) Niobium compound
CY1114823T1 (el) Φαινυλ-αλκυλ πιπεραζινες οι οποιες διαθετουν μια ρυθμιστικη δραστηριοτητα του τνf
NO20083352L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20085285L (no) 2-alkosy-3,4,5-tnhydroksyalkylamidbenzazepiner, deres fremstilling og bruk samt preparater inneholdende disse
NO20073015L (no) Substituerte indoler, sammensetninger og fremgangsmate for fremstilling derav
WO2007109871A3 (en) Acridine derivatives with antitumoral activity